New Survey Results from Cloudbreak Pharma Highlight Disease Burden, Need for Non-surgical Treatment Options for Underdiagnosed and Undertreated Ocular Disease
IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma, a clinical stage biotechnology company developing ophthalmic drugs for common eye diseases with few treatment options, shared new data from a company-supported survey highlighting the patient burden of pterygium at the annual ASCRS meeting in Boston. Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.1 The cross-sectional survey revealed 50 percent of respondents